Back to results
US 12,599,581 B2Granted
Method of treating expressive language deficit in autistic humans
AssigneeAMS Therapeutics, LLC
InventorCharles E. Niesen
Life of this patent
Estimating the term…
Abstract
A pharmacological method for treating the expressive language deficit in an autistic human child or adult is provided. A therapeutically effective dose of a succinimide anticonvulsant, e.g., ethosuximide, methsuximide, phensuximide, or a pharmaceutically acceptable salt thereof, is administered to a patient suffering from expressive language deficit, preferably over an extended period, e.g., six months or longer. Language gains are retained even after treatment is discontinued.
Claims10
A method of treating expressive language deficit in an autistic, nonepileptic, adult human, comprising:
- administering ethosuximide to the autistic, nonepileptic, adult human at a dosage and for a period of time sufficient to reduce the adult human's expressive language deficit;
- wherein the dosage is at least 500 mg/day and the period of time is at least three months.
Dependencies are inferred from the claim text.